6.5. molecular factors. numerous molecular markers carbonic anhydrase ix (caix), vegf, hif, ki67 (proliferation), p53, p21 , pten (phosphatase tensin homolog) cell cycle , e-cadherin, osteopontin cd44 (cell adhesion) , cxcr4 , pd-l1 , mirna, snps, gene mutations, gene methylations investigated (le: 3) . majority markers associated prognosis many improve discrimination current prognostic models, little emphasis external validation studies. furthermore, conclusive evidence value molecular markers treatment selection mrcc . routine use clinical practice therefore recommended. several prognostic predictive marker signatures described specific systemic treatments mrcc. javelin renal 101 trial (nct02684006), 26-gene immunomodulatory gene signature predicted pfs treated avelumab plus axitinib, angiogenesis gene signature associated pfs sunitinib. mutational profiles histocompatibility leukocyte antigen (hla) types also associated pfs, programmed death-ligand 1 (pd-l1) expression tumour mutational burden . immotion151 (nct02420821), effector/ifn-Î³-high angiogenesis-low gene expression signature predicted improved pfs atezolizumab plus bevacizumab compared sunitinib. angiogenesis-high gene expression signature correlated longer pfs patients treated sunitinib . checkmate 214 (nct02231749), higher angiogenesis gene signature score associated better overall response rates pfs sunitinib, lower angiogenesis score associated higher orr treated nivolumab plus ipilimumab. progression-free survival > 18 months often seen patients higher expression hallmark inflammatory response hallmark epithelial mesenchymal transition gene sets . urinary plasma kidney-injury molecule-1 (kim-1) identified potential diagnostic prognostic marker. kim-1 concentrations found predict rcc five years prior diagnosis associated shorter survival time . kim-1 glycoprotein marker acute proximal tubular injury therefore mainly expressed rcc derived proximal tubules ccrcc prcc . early studies promising, high-quality research required. several retrospective studies large molecular screening programmes identified mutated genes chromosomal changes ccrcc distinct clinical outcomes. expression bap1 pbrm1 genes, situated chromosome 3p region deleted 90% ccrccs, shown independent prognostic factors tumour recurrence [240-242]. published reports suggest patients bap1- mutant tumours worse outcomes compared patients pbrm1-mutant tumours . loss chromosome 9p 14q consistently shown associated poorer survival [243-245]. tracerx renal consortium proposed genetic classification based rcc evolution (punctuated vs. branched vs. linear), correlates tumour aggressiveness survival . additionally, 16-gene signature shown predict disease-free survival (dfs) patients non-metastatic rcc . however, signatures validated independent researchers yet.